MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
ENDRA Life Sciences Total Liabilities 2011-2026 | NDRA
Annual Total Liabilities ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.59 M | 1.89 M | 1.1 M | 2.07 M | 2.09 M | 1.6 M | 2.42 M | 975 K | 848 K | 1.38 M | 236 K | 97.6 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.42 M | 97.6 K | 1.36 M |
Quarterly Total Liabilities ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 1.79 M | 1.33 M | 1.42 M | 1.89 M | - | 1.45 M | 1.36 M | 1.1 M | 2.41 M | 2.31 M | 2.16 M | 2.07 M | 2.14 M | 1.98 M | 1.87 M | 2.09 M | 2.16 M | 2.25 M | 1.05 M | 1.6 M | 2.03 M | 1.6 M | 1.6 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 975 K | 975 K | 975 K | 975 K | 848 K | 848 K | 848 K | 848 K | 1.38 M | 1.38 M | 1.38 M | 1.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.42 M | 848 K | 1.64 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Castle Biosciences
CSTL
|
108 M | $ 20.15 | -1.9 % | $ 584 M |  USA |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
Guardant Health
GH
|
2.11 B | $ 118.95 | 0.8 % | $ 14.9 B | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 17.11 | -1.55 % | $ 517 M | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 116.78 | 0.18 % | $ 9.63 B |  Irlanda |
 |
Agilent Technologies
A
|
5.32 B | $ 114.96 | 0.15 % | $ 34.9 B | USA |
 |
Celcuity
CELC
|
366 M | $ 138.23 | -3.02 % | $ 6.46 B | USA |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 5.07 | 36.66 % | $ 6.74 M | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
84.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
110 M | $ 21.63 | 0.28 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 144.41 | -0.29 % | $ 23 B | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.82 | 1.11 % | $ 8.05 M | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 103.0 | 9.03 % | $ 6.95 B | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 432.8 | 0.63 % | $ 12.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 103.09 | 1.16 % | $ 22.7 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.36 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 160.3 | 0.91 % | $ 7.95 B | USA |
 |
Personalis
PSNL
|
73 M | $ 8.47 | 2.67 % | $ 756 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
523 M | $ 9.23 | 1.32 % | $ 1.18 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
121 M | $ 19.08 | 0.21 % | $ 427 M | USA |
 |
Natera
NTRA
|
689 M | $ 203.19 | -0.25 % | $ 20 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 3.82 | -2.3 % | $ 354 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 26.95 | -0.74 % | $ 25.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 6.34 | 2.92 % | $ 265 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 60.57 | 2.95 % | $ 3.62 B | USA |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.49 | 2.05 % | $ 5.72 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 259.93 | 1.63 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 448.28 | -0.24 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 0.6 | -3.7 % | $ 216 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 8.9 | 0.45 % | $ 1.93 B | USA |
 |
Waters Corporation
WAT
|
2.52 B | $ 342.37 | 0.4 % | $ 20.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 195.21 | 0.72 % | $ 21.7 B | USA |